Table 3 The primary outcomes for all patients in different subgroups

Primary outcomes N(%)

Total

(N = 304)

LYM>0.8

(N = 191)

LYM ≤ 0.8

(N = 113)

P value

28-day mortality

37 (12%)

10 (5%)

27 (24%)

< 0.001

60-day mortality

49 (16%)

13 (7%)

36 (32%)

< 0.001

Total

(N = 311)

SOFA>3.0

(N = 78)

SOFA≤3.0

((N = 233)

P value

28-day mortality

36 (11%)

32 (41%)

4 (2%)

< 0.001

60-day mortality

47 (15%)

41 (53%)

6 (3%)

< 0.001

Total

(N = 302)

APACHE II>7.0

(N = 102)

APACHEII≤7.0

(N = 200)

P value

28-day mortality

36 (12%)

32 (31%)

4 (2%)

< 0.001

60-day mortality

47 (16%)

42 (41%)

5 (3%)

< 0.001

Total

(N = 215)

Pa0₂/FiO₂>200

(N = 140)

Pa0₂/FiO₂ ≤ 200

(N = 75)

P value

28-day mortality

31 (14%)

11 (8%)

20 (27%)

< 0.001

60-day mortality

42 (20%)

13 (9%)

29 (39%)

< 0.001

Total

(N = 186)

IL-6>120

(N = 11)

IL-6 ≤ 120

(N = 175)

P value

28-day mortality

20 (11%)

4 (36%)

16 (9%)

0.020

60-day mortality

27 (15%)

6 (55%)

21 (12%)

0.002

Total

(N = 296)

CRP>52

(N = 81)

CRP ≤ 52

(N = 215)

P value

28-day mortality

34 (12%)

20 (25%)

14 (7%)

< 0.001

60-day mortality

46 (16%)

28 (35%)

18 (8%)

< 0.001

Total

(N = 325)

Critical type

(N = 103)

Severe type

(N = 222)

P value

28-day mortality

42 (13%)

36 (35%)

6 (3%)

< 0.001

60-day mortality

55 (17%)

49 (48%)

6 (3%)

< 0.001